Molecular genetics, imaging and treatment of oligodendroglial tumours.
The discovery of a genetic signature of chemosensitivity and prognosis in oligodendroglial tumours prompted a new optimism in glioma management. After more than a decade since the initial reports, where do we stand in the current management of oligodendroglial tumours? This review focuses on the latest molecular genetics, imaging characteristics, and recent trials of treatment paradigms for these tumours.
Jenkinson
Michael D
MD
Department of Neurosurgery, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, L9 7LJ, UK. michael.jenkinson@liv.ac.uk
Walker
Carol
C
Brodbelt
Andrew R
AR
Wilkins
Simone
S
Husband
David
D
Haylock
Brian
B
D024221:Antineoplastic Protocols / Q000592:standards; D001921:Brain / Q000473:pathology* / Q000503:physiopathology; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D003131:Combined Modality Therapy / Q000379:methods / Q000639:trends; D003952:Diagnostic Imaging / Q000379:methods / Q000639:trends; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D008967:Molecular Biology / Q000379:methods / Q000639:trends; D009837:Oligodendroglioma / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D011379:Prognosis; D015996:Survival Rate / Q000639:trends